Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial

by Emu, Brinda, Luca, Diana, Offutt, Carolyn, Grogan, Jane L, Rojkovich, Bernadette, Williams, Marna B, Tang, Meina T, Xiao, Jim, Lee, June H, Davis, John C
Published 2012

Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)

by Kennedy, William P, Simon, J Abraham, Offutt, Carolyn, Horn, Priscilla, Herman, Ann, Townsend, Michael J, Tang, Meina T, Grogan, Jane L, Hsieh, Frank, Davis, John C
Published 2014